WEBINAR: AI-Driven Platforms for Biologics Development and Manufacturing скачать в хорошем качестве

WEBINAR: AI-Driven Platforms for Biologics Development and Manufacturing

10 Feb 2026 5.30-6.30pm SGT | Online ABSTRACT The success of cell therapy is fundamentally constrained by the cost, scalability, and consistency of cell manufacturing, with ex vivo T-cell expansion and quality remaining a major bottleneck for the field. Recent advances in AI-enabled virtual cell model and drug discovery offer a new approach to modulating cell function, enabling more precise control over cell expansion, phenotype, and viability. The real application suggests that rationally designed small molecules can significantly enhance T-cell expansion while preserving naïve and memory phenotypes critical for long-term therapeutic efficacy. Such platforms point toward a promising approach by leveraging AI toward more reproducible, scalable, and cost-effective manufacturing strategies for next-generation cell and gene therapies. LED BY Dr. Ling Wu, President & Co-Founder, ChemT Biotechnology, Singapore ChemT Biotechnology is a TechBio company that leverages AI to design cellular drugs for precise and tunable cellular control for biologics manufacturing. Dr. Wu brings about 15 years of experience in biopharma research. He previously served as principal investigator and leading the cell and gene therapy research team at BeiGene, now named BeOne Medicine.